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General experimental procedures. Optical rotation measurements were obtained on a Perkin-Elmer 241 Polarimeter calibrated using a Rudolph 
Quartz Control Plate Calibration Standard at sodium D line (at +11.502°). Ultraviolet spectra were obtained on a UV-visible Molecular Devices 
SpectraMax M5 spectrophotometer using 1-ml cuvettes with 1.0 cm path lengths at room temperature in solvent methanol (MeOH). 
Spectrophotometric assays were performed on Molecular Devices SpectraMax M5 384 variable wavelength spectrometer. All NMR spectra were 
acquired on a Varian INOVA 600MHz spectrometer at the NMR Facility, Life Sciences Institute, University of Michigan. HRESIMS spectra were 
measured at the University of Michigan core facility in the Department of Chemistry using an Agilent 6520 Q-TOF mass spectrometer equipped 
with an Agilent 1290 HPLC system. RP-HPLC was performed using Econosil C18 10 mm 22×250-mm column and Agilent ZORBAX RX-C8 5 
mm 9.4×250-mm column and a solvent system of MeCN and H2O. The LC-MS analysis of HPLC fractions was performed on a Shimadzu 2010 
EV APCI spectrometer. 
Protein Expression, Purification. The cahJ gene was amplified by PCR from genomic DNA of S. gandocaensis using the primer SR235 (5’-
GCCGCGCGGCAGCCATATGCTCGATGGGTGGGTG-3’) and SR236 (5’-TCGAGTGCGGCCGCAAGCTTCAGTGGACACCGCCGTC -3’). 
Cloning of cahJ gene into pET28b (Novagen) for expression of N-terminal His6-tagged CahJ was performed using Gibson assembly [1] master 
mix (New England Biolabs). The amplified PCR product of cahJ and pET28b, which had been cut by EcoRI and HindIII, were incubated at 50°C 
for 2 h. Following incubation, the samples were transformed into E. coli DH5α and isolated. The accuracy of cahJ in pET28b was confirmed by 
restriction digestion and sequencing. Synthetic codon-optimized DNA encoding the CahA ArCP was purchased from IDT, inserted into the 
pMCSG7 vector using LIC cloning [2], and verified by sequencing.  
Protein Expression and Purification. Recombinant plasmid pET28b-cahJ was utilized to transformed into Escherichia coli BL21(DE3)/pRARE 
cells. The resulting transformant was grown at 37 °C in 1 liter of LB broth containing kanamycin (50 μg/ml) until OD600 reached 0.6~1.0. Then, 
isopropyl-β-D-thiogalactopyranoside (IPTG) was added to a final concentration of 0.2 mM to induce gene expression and cells were cultured at 
18°C overnight. Cells were harvested by centrifugation at 5,000 × g for 10 min at 4°C to harvest cells. The cell pellet was resuspended in 70 ml 
of lysis buffer (50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, 10% glycerol, 0.1mM EDTA (pH8.0), 0.2mM TCEP, pH7.6) and lysed by 
sonication. Cell debris was removed by centrifugation for 20 min at 45,000 × g. The supernatant was mixed with 1 ml of Ni-NTA agarose (Qiagen) 
for 1 h at 4 °C and loaded onto an empty column. The column was washed with 50-100 ml of wash buffer (50 mM NaH2PO4, 300 mM NaCl, 20 
mM imidazole, 10% glycerol, 0.2mM TCEP, pH7.6). The bound His6-tagged proteins were eluted with elution buffer (50 mM NaH2PO4, 300 mM 
NaCl, 250 mM imidazole, 10% glycerol, 0.2mM TCEP, pH 8.0). The CahJ (59 kDa) proteins were further purified and concentrated with 30K size 
exclusion filters (Amicon). Buffer exchange with storage buffer (50 mM NaH2PO4, 10% glycerol, pH7.3) using a PD-10 column (GE Healthcare) 
was used to lower the sample’s salt concentration. Protein concentration was determined using NanoDrop spectrophotometer. The molar 
extinction coefficient for CahJ at A280 is 52,370 M-1cm-1. 
Expression and Purification of CahA ArCP and CahJ for crystallization. Cultures were grown in either Terrific Broth (TB) medium containing 
4% glycerol or in M9 minimal medium supplemented with nutrient mix (AthenaES) and L-methionine (Sigma) as indicated. Ampicillin (100 μg/mL, 
pMCSG7), spectinomycin (50 μg/mL, pRARE), and kanamycin (50 μg/mL, pET28b) were used with the corresponding plasmids in E. coli cultures. 
E. coli strain BAP1 [3] was transformed with pMCSG7-cahA_ArCP, and strain BL21-AI (Thermofisher) was transformed with pET28b-cahJ. Both 
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strains contained the pRARE plasmid [4]. Cultures were grown at 37°C in 500 mL TB with 4% glycerol to an OD600 of 1.5, cooled to 20°C for at 
least 1 hr, induced with IPTG (final concentration 0.2 mM), and grown for an additional 14-18 hr before harvesting by centrifugation. Cell pellets 
were stored at -20°C until used for protein purification. Minimal media cultures were moved to 20°C at an OD600 of 0.6, but were otherwise 
treated identically to rich media cultures. 
Cell pellets were resuspended in approximately 5 mL Buffer A (50 mM HEPES pH 7.6, 250 mM NaCl, 5% glycerol) containing 15 mM imidazole 
per 1 g cell paste. All purification steps were performed at 4°C. Resuspended cells were incubated with DNase (4 mg), lysozyme (10 mg), and 
MgCl2 (4 mM) for 30 min, then lysed by three passes through an Avestin EmulsiFlex-C3 homogenizer. The lysate was clarified by centrifugation 
at 30,000xg in a Sorvall F21-8x50y rotor. The soluble fraction was filtered through 0.45 μm and 0.22 μm filters and then loaded onto a 5-mL 
HisTrap Ni NTA column (GE Healthcare) and eluted with an imidazole gradient up to 300 mM in Buffer A. The eluate was concentrated to 
approximately 5 mL using a 50 kDa Amicon Ultra-15 membrane, centrifuged at 20,000xg for 30 min, then loaded onto a HiLoad 16/600 Superdex 
200 column (GE Healthcare) equilibrated with Buffer B (20 mM Tris pH 7.5, 150 mM NaCl, 10% glycerol) and isocratically eluted. Fractions were 
pooled, concentrated as above to 20-30 mg/mL, centrifuged at 20,000xg for 30 min, flash frozen in 20-50 μL aliquots with liquid N2, and stored at 
-80°C. CahJ co-purified with bound SA adenylate from cells grown in rich media and with bound benzoyl adenylate from cells grown in minimal 
media. These co-purifying ligands were removed from CahJ by inserting the following steps while the protein was bound to the HisTrap Ni NTA 
column, prior to elution with imidazole: 10 CV linear gradient of 0 to 500 mM urea in Buffer A; 5 CV wash; 10 CV linear gradient of 500 mM to 0 
urea in Buffer A containing 1 mM AMP; and 5 CV wash with Buffer A containing 30 mM imidazole.  
CahA ArCP was purified identically to CahJ except that the buffer was 100 mM Tris pH 7.5, 500 mM NaCl, 10% glycerol, 5 mM TCEP. The eluate 
was concentrated using a 10 kDa Amicon Ultra-15 to approximately 10 mg/mL. CahA was then incubated for 16 hr at 30°C with the 
phosphopantetheinyl transferase Sfp [5] at a 1:40 ratio in a reaction mix containing 16 mM ATP, 4 mM pantethine, 4 mM DDT, and 0.2 mg/mL of 
CoaA, CoaD, and CoaE [6]. After incubation, protein was centrifuged at 20,000 xg for 30 min and then loaded onto a HiLoad 16/600 Superdex 75 
column (GE Healthcare) equilibrated with 100 mM Tris pH 7.5, 250 mM NaCl, 5% glycerol, 5 mM TCEP and isocratically eluted. Fractions were 
pooled, concentrated to 10 mg/mL, centrifuged at 20,000 xg for 30 min, flash frozen in 20-30 μL aliquots with liquid N2, and stored at -80°C.  
Crystallization. Frozen CahJ stock solution was thawed on ice and glycerol was removed by buffer exchange into 20 mM Tris pH 7.5, 150 mM 
NaCl using a 50K Amicon Ultra 0.5 membrane. After addition of the appropriate substrates (final concentration for all 1.5 mM, Table 1), the 
mixture was diluted to a final concentration of 20 mg/mL CahJ, incubated on ice for 30 min, and clarified by centrifugation at 20,000xg for 30 min 
at 4°C. Crystals grew in approximately one week at 20°C by vapor diffusion in 1.5-μL sitting drops containing equal volumes of protein stock and 
reservoir solution (0.08-0.14 M sodium cacodylate pH 6.5, 1.5 - 2.0 M sodium acetate). Crystals were harvested in nylon loops, cryoprotected in 
reservoir solution containing 20% glycerol, and flash cooled in liquid N2.  
Diffraction Data Collection and Structure Determination. Diffraction data were collected at 100 K on GM/CA beamline 23ID-D at the Advanced 
Photon Source (APS) at Argonne National Laboratory (Argonne, IL). For each crystal, 360º of data were collected at an X-ray energy of 12 keV 
with 0.2º rotation and 0.2 sec exposure per image. Data were processed using XDS [7]. The structure of CahJ with bound AMP and salicylic acid 
was solved by molecular replacement (MR) with Phaser [8] in the PHENIX [9] software suite from the DhbE structure [10] (58% identity, PDB code: 
1MD9) with the C-terminal domain removed. The initial model from MR was modified with AutoBuild [11] to generate a 75% complete model of 
CahJ. The remaining portion of model was completed manually using Coot [12]. Refinement was performed using phenix.refine [13]. Structures of 
SUPPORTING INFORMATION          
4 
 
CahJ with other ligands were solved by difference Fourier methods as the crystals were isomorphous. Restraints for all substrates, except AMP, 
were generated using eLBOW [14]. Images and figures were prepared using PyMOL [15]. 
Determination of Substrate Specificity and Kinetic Parameters. The substrate selectivity of CahJ was determined using a non-radioactive 
colorimetric assay [16]. All assays were performed in 384-well reaction plates. To perform the assays, benzoic acid substrates were prepared in 
DMSO and 10 μl was transferred in triplicate to a 384-well reaction plate. Reactions were initiated by adding the mixture (40 μl) containing 
recombinant CahJ (6 μM), inorganic pyrophosphatase (0.2 U/ml), ATP (0.5 mM), NaCl (100 mM), MgCl2 (10 mM), substrates (20 μM), and 50 mM 
Tris–HCl (pH 7.5) and incubated at RT. The reactions were terminated after 10 min by the addition of molybdate/malachite green reagent (10 μl). 
After 10 min of color development, the released Pi concentration was monitored at 600 nm on a microplate reader (SpectraMax®). For the 
determination of Km and Kcat for formation of SA adenylate (SA-AMP) and 6-MSA adenylate (6-MSA-AMP), reactions were done with varying 
concentrations of SA and 6-MSA (1.25 μM, 2.5 μM, 5.0 μM, 10.0 μM, and 20.0 μM) in the same condition as described above. The reactions 
were incubated at RT and stopped after 0, 5 and 10 min by the addition of molybdate/malachite green reagent (10 μl). A reaction mixture without 
the recombinant CahJ domain was used as a negative control. The experiments were carried out in triplicate for each substrate concentration.  
CahJ Mass Spectrometry Assays with ArCP. Reactions in 25 μL mixtures (50 mM Tris pH 7.8, 100 mM NaCl, 10 mM MgCl2, 500 μM ATP, 2 
μM CahJ, and 20 μM ArCP) were initiated by addition of 500 μM substrate in DMSO (final concentration 0.5% DMSO), incubated at 25°C for 1 
hr, quenched by the addition of 10% formic acid, and stored at 4°C prior to analysis. 1 μL of reaction mixture was used for LC-MS analysis (Agilent 
6545 Q-TOF equipped with Agilent 1290 HPLC system). Samples were separated for intact protein analysis by RP-HPLC (Aeris widepore C4 
column 3.6 μM, 50 X 2.10 mm) with a 10 min gradient of 10-95% acetonitrile with 0.1% formic acid at a flow rate of 0.5 mL/min. Data were 
analyzed using the Agilent Mass Hunter Qualitative Analysis software with the maximum entropy deconvolution algorithm. A reaction mixture 
without CahJ was used as a negative control. 
Generation of Cahuitamycin Analog through Mutasynthesis. Mutant strain of ΔcahI (DHS334) was first pre-cultured in 3ml R2YE liquid 
medium for 15 days at 28 °C and then 3ml of the seed culture was used to inoculate 100 ml of the same medium, followed by cultivation for 15 
days at 28 °C. Salicyclic acid (as positive control) and 4-methylsalicylic acid were added every alternate day to separate 100 mL cultures of ΔcahI 
at a final concentration of 500 µM for 10 days. The products were first extracted using Amberlite XAD-16. The resin was separated and subjected 
to organic extraction using MeOH:EtOAc (1:1) for LC-MS analysis as described above.  
The substrate-fed crude extract was then further purified by RP-HPLC on a gradient of 10–75% ACN and was followed by ultraviolet–visible 
photodiode array detection at 215 nm to yield semi-pure compounds 1 (4.3 mg). Compounds were again subjected to re-purification over RP-
HPLC on isocratic condition of 35% MeOH (0.1% FA) using C-8 column to get compounds 1 (2.1 mg). 
Cahuitamycin F (1). Amorphous powder; ultraviolet (ACN: H2O) λmax 204, 240, 252 and 304 nm; 1H and 13C NMR, see Table S2; HRESIMS m/z 
650.2706 [M+H]+ (calculated for C28H40N7O11, 650.2786). 
Minimum Inhibitory Concentration Test. Cultures of A. baumannii ATCC 17978 grown overnight were diluted into fresh 10% Mueller Hinton II 
broth to get 105 colony-forming units per ml by determining optical density at OD600. A volume of 100 ml of diluted cultures were incubated in 
individual wells of 96-well plate containing 1% of DMSO and various concentrations of cahuitamycins A (3) and F (1). The plate was incubated at 
30°C with shaking at 150 r.p.m. The optical density of each well was monitored every 1 hr up to 24 hrs using a microtiter plate reader (Synergy 
HT, Bio-Tek, Winooski, VT). The number of viable bacterial cells was determined by counting colony-forming units.  
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Biofilm Dispersal Assay. The biofilm dispersal assay was performed as previously reported [17]. Briefly, A. baumannii ATCC 17978 biofilm was 
developed as described in minimum inhibitory concentration test. After 16 h incubation at 30 °C, the suspension in each well was removed by 
pipetting gently. A volume of 100 ml of 1% PBS buffer containing cahuitamycins A (2) and F (1) at various concentrations was placed into each 
well. The plate was incubated at 30 °C for 12 h to allow cahuitamycins to disassemble pre-formed biofilms. Then, the suspension was removed 





Figure S1: Proposed biosynthesis of cahuitamycins A-C in S. gandocaensis. The CahJ-dependent adenylation of salicylic acid and 6-methylsalicylic acid in cahuitamycin assembly is an ATP-
















































Figure S2. Structure based sequence alignment of CahJ with adenylation domains from E. coli (EntE), A. baumannii (BasE), and B. subtilis (DhbE). Conserved residues are 
shown in white on a red background and similar residues are shown in red font. Secondary structure for CahJ is shown above the alignment (α for α-helix and β for β-strand, 
TT for β-turn and η for 310 helix). 
 





Figure S3: A) Coomassie blue-stained SDS-PAGE gel ran in Bis-Tris buffer for CahJ. B) Representative data of CahJ activity for SA and 6-MSA by malachite green assay. SA 






















Figure S4: Intact protein mass spectra of CahJ loading of SA and 6-MSA onto CahA ArCP. CahJ was incubated 1 hr with either SA or 6-MSA and ArCP, in both cases leading 
to complete conversion of holo-ArCP to aryl-ArCP. NEC is a no enzyme control. Calculated and observed masses for ionized species are listed in Supplemental Table S3. 
 




Figure S5: Intact protein MS of CahJ loading of unnatural substrates onto CahA ArCP. CahJ was incubated 1 hr with benzoic acid (A), 3-MSA (B), 4-MSA (C), 5-MSA (D), or 
2-fluorobenzoic acid and ArCP, in all cases there was complete conversion of holo-ArCP to substrate loaded ArCP. NEC is a no enzyme control. Calculated and observed 
masses for ion species can be found in Table S3. 




Figure S6: CahJ interaction with substrate adenylates, generated by LigPlot+ (Laskowski and Swindells, 2011).  A) 5-MSA adenylate. B) 6-MSA adenylate. C) Benzyl 
adenylate. D) SA adenylate. E) Overlay of the four previous LigPlots. Red circles indicate contacts observed in multiple substrate complexes.  




Figure S7: HRRESIMS [M+H]+ chromatogram of cahuitamycin F (1). 
 
 
























































Figure S13: 2D HMBC NMR spectrum of cahuitamycin F (1). 
 
 
Table S1: Protein production and crystal growth conditions plus data collection and refinement statistics for CahJ structures. 





aValues in parentheses pertain to outermost shell of data
CahJ complex AMP + SA Salicyl adenylate 5-MSA adenylate 6-MSA adenylate Benzoyl adenylate AMP 
CahJ production Rich media, urea treatment Rich media Rich media, urea treatment Rich media, urea treatment Minimal media Rich media, urea 
treatment 
Added ligands AMP, SA none ATP, 5-MSA ATP, 6-MSA none AMP 
Data Collection       
Space group P3221 P3221 P3221 P3221 P3221 P3221 
Cell dimensions a/b,c (Å) 122.1, 87.7 122.4, 88.1 122.0, 87.7 122.2, 88.2 121.7, 87.9 122.0, 88.0 
X-ray source APS 23ID-D APS 23ID-D APS 23ID-D APS 23ID-D APS 23ID-D APS 23ID-D 
Wavelength (Å) 1.033 1.033 1.033 1.033 1.033 1.033 
dmin (Å) 1.55 (1.64-1.55)a 1.68 (1.78-1.68) 1.80 (1.91-1.80) 1.78 (1.89-1.78) 2.0 (2.12-2.0) 1.78 (1.88-1.78) 
Rmerge 0.079 (0.955) 0.120 (0.584) 0.097 (1.20) 0.090 (0.822) 0.140 (0.75) 0.098 (0.777) 
Wilson B factor 24.8 29.6 33.6 31.4 28.6 27.2 
Avg I/σ(I) 20.47 (2.43) 5.86 (1.54) 8.96 (1.19) 10.41 (1.50) 8.35 (1.71) 11.37 (1.76) 
Completeness (%) 99.9 (99.6) 98.9 (98.4) 98.9 (99.2) 99.1 (99.3) 99.4 (99.4) 96.1 (95.1) 
Multiplicity 10.02 (9.71) 3.39 (3.32) 3.40 (3.40) 3.93 (3.84) 3.39 (3.35) 4.06 (4.02) 












CC1/2 0.999 (0.637) 0.985 (0.663) 0.996 (0.414) 0.997 (0.517) 0.986 (0.422) 0.996 (0.458) 
CC* 0.999 (0.882) 0.996 (0.893) 0.999 (0.765) 0.999 (0.823) 0.996 (0.770) 0.999 (0.793) 
Refinement       
Data range (Å) 35.60-1.55 35.76-1.68 18.51-1.80 35.76-1.78 35.64-2.0 35.68-1.78 
Reflections used in refinement 109,137 85,969 69,218 72,133 50,752 70,015 
Rwork/Rfree (%) 13.0/16.0 17.4/20.4 15.6/19.3 15.5/19.4 13.8/17.5 14.3/17.5 
Twin fraction 0.29 0.04 0.12 0.17 0.49 0.47 
Non-hydrogen atoms 4,701 5,001 4651 5,025 4,506 4481 
  protein 4,125 4,079 4056 4,083 4,070 4047 
  ligands 43 58 47 68 36 23 
  water 533 864 548 874 400 411 
Amino acid residues 536 537 536 537 536 536 
Deviation from ideality       
  bond lengths (Å) 0.006 0.007 0.008 0.008 0.007 0.007 
  bond angles (°) 0.84 0.923 0.97 0.84 0.87 0.86 
Average B-factor (Å2) 20.3 27.5 32.1 23.8 23.1 20.3 
  macromolecules 18.4 24.7 30.5 21.2 22.4 19.6 
  ligands 27.0 23.5 29.1 21.3 14.7 17.2 
  solvent 35.3 40.9 44.2 36.1 30.5 27.3 
Ramachandran plot       
  favored (%) 96.9 97.8 98 97.6 97.0 97.2 
  allowed (%) 2.9 2.0 1.8 2.0 2.8 2.6 
  outliers (%) 0.2 0.2 0.2 0.4 0.2 0.2 
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Table S2: NMR spectroscopic data for cahuitamycins F (1). 
  Cahuitamycin F (1) 
  δC δH, multi (J in Hz) COSY HMBC 
1 174.1       
2 36.5 2.37, m  3 1 
   2.41, m    
3 36.9 3.37, m 2 1 
    3.51, m 2 4 
4 167.3     
5 50.8 4.41, dd (4.5, 9.5) 6 4, 9 
6 28.1 1,78, m 5, 7   
    1.98, m 5, 7   
7 20.9 1.92, m 6, 8 5 
    1.99, m 6, 8   
8 52.5 3.57, m 7 9 
    3.62, m 7 6 
9 173.2     
10 54.4 4.30, dt (6.0, 14.0) 11 9, 11, 15 
11 29.1 1.62, m 12, 10   
    1.84, m 10   
12 23.5 1.63, m 11, 13 13, 10 
    1.68, m 11, 13 10 
13 51.1 3.43, t (6.4, 13.0) 12 11, 14 
     
14 163.1 7.78, s    
15 172.5     
16 56.9 4.47, m 17 15, 18 
17 62.6 3.89, d (5.0) 16 15 
18 173.8     
19 68.9 5.10, dd (7.5, 10.0)  20 18 
20 70.4 4.59, dd (7.5, 9.0) 19 18, 21 
    4.68, dd (8.0, 9.0) 19 21 
21 168.7     
22 146.5     
23 129.3 7.58, d (7.0)  24 21, 22, 28 
24 121.6 6.77, d (7.0 23 26, 27 
25 108.6    
26 21.3 2.31, s  24, 25, 27 
27 117.7 6.82, s  28 24, 25, 26 










Table S3: Calculated and observed ion masses from intact protein MS assay. 
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